Effects of sodium-glucose cotransporter-2 inhibitor empagliflozin on central hemodynamics in patients with heart failure and heart failure with reduced ejection fraction
Latest Information Update: 09 Dec 2020
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure
- Focus Therapeutic Use
Most Recent Events
- 09 Dec 2020 Primary endpoint (peak exercise PCWP/CI ratio 12 weeks') has not been met.
- 09 Dec 2020 New trial record
- 08 Dec 2020 Results published in the Journal of the American College of Cardiology.